What does Vogenx, Inc. do?
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1…
What is Vogenx, Inc.'s P/E and P/B ratio?
Vogenx, Inc. has a P/E ratio of -86.7 and a P/B ratio of -159.30.
What is Vogenx, Inc.'s debt-to-equity ratio?
Vogenx, Inc. has a debt-to-equity ratio of -0.89.
How much does Vogenx, Inc. owe compared with what it owns?
Vogenx, Inc. owes $2.26 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Vogenx, Inc.'s Positivity rank?
Vogenx, Inc. is ranked #6,730 of 6,775 companies globally and #3,959 of 4,000 in United States on PositoAI, with a Positivity Score of -98,917.
Does Vogenx, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Vogenx, Inc..
Where can I read the latest news about Vogenx, Inc.?
Recent headlines about Vogenx, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Vogenx, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Vogenx, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.